What happens when the guidelines and my experience disagree?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
The guideline gets stated first, plainly, including how strong the recommendation is. A specialist may then reasonably diverge for an individual patient, and the 2011 Institute of Medicine report on trustworthy guidelines says so: recommendations inform the encounter rather than impose one rule on everyone. What is not acceptable is diverging without explaining why, or presenting a preference as evidence.
Both get stated out loud. The guideline is named, along with how strong the recommendation is and what evidence sits behind it. Your experience is recorded as what it is: information about you that the guideline was not written about. A specialist can reasonably depart from a guideline for an individual patient. What is not defensible is departing without saying so, or presenting a personal preference as though it were evidence.
What a guideline is, and what it is not
A clinical practice guideline is a set of recommendations built from a systematic review of evidence. The 2011 Institute of Medicine report Clinical Practice Guidelines We Can Trust describes their purpose as translating research findings into recommendations relevant to the individual patient encounter, "instead of implementing a one size fits all approach to patient care". Guidelines also carry strength labels, and the label matters. A strong recommendation means most patients should receive the intervention. A weak or conditional recommendation means the balance is close and the decision depends on the person in front of you.
Where divergence is legitimate, and where it is not
Divergence is legitimate where the guideline itself leaves room. Whether to treat subclinical hypothyroidism depends on the TSH, antibody status, age, symptoms and pregnancy plans, and reasonable specialists disagree at the margins. Combination thyroid therapy is another: the American Thyroid Association's patient guidance acknowledges that some people may need liothyronine added if they do not feel better on levothyroxine alone. Some departures are not defensible whatever anyone prefers. Leaving overt hypothyroidism untreated. Withholding insulin in type 1 diabetes. Prescribing a GLP-1 to someone with a personal or family history of medullary thyroid carcinoma. In those the evidence is not close, and preference does not change the physiology.
| Situation | What the guidance says | Room for an individual decision |
|---|---|---|
| Subclinical hypothyroidism, TSH 6.0 mIU/L, TPO positive, symptomatic, age 38 | Treatment is optional at this level | Yes, a time limited trial with a defined endpoint is reasonable |
| Overt hypothyroidism with a TSH of 30 mIU/L | Levothyroxine replacement | No |
| Adding liothyronine to levothyroxine | Not the routine first choice, but the ATA acknowledges some people may need it | Yes, as a monitored trial with a stopping rule |
| Hormone therapy started at 68, many years after menopause | The 2022 Menopause Society statement places the most favourable safety profile under 60 or within 10 years of menopause | Limited; a different route or indication may still apply |
| GLP-1 with a family history of medullary thyroid carcinoma | Contraindicated on the FDA labels | No |
Where opinion belongs
This library states what the guidelines say. Where Dr. Sater holds a position that goes beyond a guideline, it belongs in the Dr. Z Journal, labelled as her view, with the reasoning shown and the guideline it departs from named. The separation is deliberate. Someone reading a reference page should see the standard of care first and the argument second, and should be able to tell at a glance which one they are reading.
In your own appointment, ask two questions whenever you are told something is or is not recommended. Which guideline, and is that a strong or a weak recommendation? And what specifically about my case makes you depart from it? Both answers should be short, and both should end up written in your record.
The clinical detail
Recommendation strength is not the same as evidence quality, and reading both changes how much weight a statement carries. In GRADE based guidelines a strong recommendation implies most well informed patients would choose the intervention, while a conditional recommendation implies choices will reasonably differ. A strong recommendation can rest on low quality evidence where harm is severe, and a conditional recommendation can rest on high quality evidence where the benefit is small.
Practical consequence: for conditional recommendations, the appropriate record is a shared decision with a stated endpoint. A trial of liothyronine, or of levothyroxine in subclinical hypothyroidism, should have the target symptom, the review interval and the stopping criterion written down before it starts, otherwise a trial becomes a permanent prescription by default.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- Clinical Practice Guidelines We Can Trust. Institute of Medicine, National Academies Press
- Hypothyroidism in Adults, patient information. American Thyroid Association
- ATA Guidelines and Statements, guideline index with publication years. American Thyroid Association
- Hormone Therapy Position Statement 2022, guideline summary. The North American Menopause Society, summary via Guideline Central
- WEGOVY (semaglutide) injection, prescribing information. U.S. Food and Drug Administration
- Type 1 Diabetes. National Institute of Diabetes and Digestive and Kidney Diseases
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.